Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12817727 | 1.00 | MAPT (0.55) | MAPTNPC1RAB9ALMNAHPGD | |
| SCHEMBL14699621 | 0.86 | RAB9A (0.55) | MAPTNPC1RAB9ALMNAHPGD | |
| SCHEMBL14699615 | 0.86 | RAB9A (0.55) | MAPTNPC1RAB9ALMNAHPGD | |
| SCHEMBL14699617 | 0.86 | MAPT (0.55) | MAPTNPC1RAB9ALMNAHPGD | |
| SCHEMBL17988727 | 0.86 | ALDH1A1 (0.61) | MAPTNPC1RAB9ALMNAHPGD | |
| SCHEMBL17988682 | 0.84 | FASN (0.51) | MAPTNPC1RAB9ALMNAHPGD | |
| SCHEMBL14699620 | 0.81 | MAPT (0.55) | MAPTNPC1RAB9ALMNAHPGD | |
| SCHEMBL38787 | 0.81 | MAPT (0.55) | MAPTNPC1RAB9ALMNAHPGD | |
| SCHEMBL17991979 | 0.80 | ACHE (0.53) | MAPTNPC1RAB9ALMNAESR1 | |
| SCHEMBL8655588 | 0.79 | NPC1 (0.65) | MAPTNPC1RAB9ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355644-A1 | ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 | CREATIVE THERAPEUTICS GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355644-A1 | ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 | CREATIVE THERAPEUTICS GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| WO-2022063549-A1 | ACTIVE SUBSTANCES AND DRUGS FOR THERAPY OF VIRAL DISEASES, PARTICULARLY CORONA INFECTIONS, MORE PARTICULARLY COVID-19 | CREATIVE THERAPEUTICS GMBH (DE) | 2022-03-31 | — | — | WO | disclosed |
| US-8426390-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| EP-2557075-A1 | New triazene compounds for treating cancer | Trin Therapeutics GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355644-A1 | ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 | ACE, ACE2, SARS1 | MAPT 847/4885NPC1 298/4885RAB9A 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.